NASDAQ:GNLX Genelux (GNLX) Stock Price, News & Analysis $2.19 +0.27 (+14.06%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.95▼$2.2050-Day Range$1.71▼$5.0252-Week Range$1.71▼$30.44Volume150,791 shsAverage Volume196,958 shsMarket Capitalization$75.23 millionP/E RatioN/ADividend YieldN/APrice Target$32.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Genelux alerts: Email Address Genelux MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,376.4% Upside$32.33 Price TargetShort InterestHealthy4.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingSelling Shares$263,750 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.86) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.53 out of 5 starsMedical Sector518th out of 936 stocksPharmaceutical Preparations Industry237th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingGenelux has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenelux has only been the subject of 2 research reports in the past 90 days.Read more about Genelux's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.96% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Genelux has recently decreased by 18.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenelux does not currently pay a dividend.Dividend GrowthGenelux does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNLX. Previous Next 3.9 News and Social Media Coverage News SentimentGenelux has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Genelux this week, compared to 1 article on an average week.Search Interest2 people have searched for GNLX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows10 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $263,750.00 in company stock.Percentage Held by InsidersOnly 9.30% of the stock of Genelux is held by insiders.Percentage Held by InstitutionsOnly 37.33% of the stock of Genelux is held by institutions.Read more about Genelux's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Genelux are expected to decrease in the coming year, from ($0.86) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genelux is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genelux is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenelux has a P/B Ratio of 3.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genelux's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.Take these 4 steps to protect your retirement here. About Genelux Stock (NASDAQ:GNLX)Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Read More GNLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNLX Stock News HeadlinesJuly 10, 2024 | insidertrades.comGenelux Co. (NASDAQ:GNLX) Insider Caroline Jewett Sells 4,961 SharesJuly 19, 2024 | barrons.comGenelux Corp.July 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” May 24, 2024 | msn.comWhy Genelux Corporation (GNLX) Shares Are Down 40%May 24, 2024 | globenewswire.comGenelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying WarrantsMay 23, 2024 | globenewswire.comGenelux Corporation Announces Proposed Public Offering of Common Stock and WarrantsMay 16, 2024 | finance.yahoo.comGenelux Corporation (GNLX)May 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Genelux Corp on Strong Trial Progress and Solid FinancialsJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” May 10, 2024 | investorplace.comGNLX Stock Earnings: Genelux Misses EPS for Q1 2024May 9, 2024 | globenewswire.comGenelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business UpdatesMay 5, 2024 | finance.yahoo.comGenelux Corporation's (NASDAQ:GNLX) market cap rose US$11m last week; individual investors who hold 54% profited and so did insidersApril 20, 2024 | investing.comGenelux Corp insider sells shares worth over $250kApril 17, 2024 | msn.comGenelux (GNLX) Price Target Decreased by 22.96% to 26.52April 2, 2024 | investorplace.comGNLX Stock Earnings: Genelux Misses EPS for Q4 2023April 1, 2024 | globenewswire.comGenelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | seekingalpha.comAtossa climbs after cancer therapy updateMarch 15, 2024 | msn.comTD Cowen cuts Immuneering to market perform, cites Phase 1 dataSee More Headlines Receive GNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GNLX CUSIPN/A CIK1231457 Webwww.genelux.com Phone805-267-9889FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$32.33 High Stock Price Target$40.00 Low Stock Price Target$25.00 Potential Upside/Downside+1,376.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,300,000.00 Net MarginsN/A Pretax Margin-322,287.50% Return on Equity-125.58% Return on Assets-86.03% Debt Debt-to-Equity RatioN/A Current Ratio2.72 Quick Ratio2.72 Sales & Book Value Annual Sales$170,000.00 Price / Sales442.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book3.00Miscellaneous Outstanding Shares34,350,000Free Float31,157,000Market Cap$75.23 million OptionableNot Optionable Beta-1.58 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Thomas Zindrick J.D. (Age 64)Chairman, CEO & President Comp: $570.99kMs. Lourie S. Zak (Age 60)Chief Financial Officer Comp: $346.19kMs. Caroline Jewett (Age 59)VP & Head of Quality Comp: $269.26kDr. Joseph Cappello Ph.D. (Age 67)Chief Technical Officer Comp: $213.08kMr. Sean Ryder J.D. (Age 54)General Counsel & Corporate Secretary Comp: $380kDr. Yong Yu Ph.D. (Age 52)Senior Vice President of Clinical Development Comp: $242.62kProf. Paul Scigalla M.D. (Age 78)Ph.D., Chief Medical Officer Mr. Ralph Smalling B.Sc. (Age 67)VP & Head of Regulatory Affairs More ExecutivesKey CompetitorsEnanta PharmaceuticalsNASDAQ:ENTAAtea PharmaceuticalsNASDAQ:AVIRVerrica PharmaceuticalsNASDAQ:VRCAAlimera SciencesNASDAQ:ALIMAquestive TherapeuticsNASDAQ:AQSTView All CompetitorsInsiders & InstitutionsAMG National Trust BankBought 25,000 shares on 7/25/2024Ownership: 0.219%Miracle Mile Advisors LLCBought 30,000 shares on 7/18/2024Ownership: 0.087%LifeSteps Financial Inc.Bought 22,227 shares on 7/17/2024Ownership: 0.194%Sean RyderSold 5,496 sharesTotal: $11,651.52 ($2.12/share)Caroline JewettSold 4,961 sharesTotal: $10,517.32 ($2.12/share)View All Insider TransactionsView All Institutional Transactions GNLX Stock Analysis - Frequently Asked Questions How have GNLX shares performed this year? Genelux's stock was trading at $14.01 at the beginning of 2024. Since then, GNLX shares have decreased by 84.4% and is now trading at $2.19. View the best growth stocks for 2024 here. How were Genelux's earnings last quarter? Genelux Co. (NASDAQ:GNLX) posted its earnings results on Thursday, May, 9th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.08. The company had revenue of $0.01 million for the quarter. When did Genelux IPO? Genelux (GNLX) raised $16 million in an initial public offering on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets served as the underwriters for the IPO. Who are Genelux's major shareholders? Genelux's top institutional shareholders include AMG National Trust Bank (0.22%), LifeSteps Financial Inc. (0.19%) and Miracle Mile Advisors LLC (0.09%). Insiders that own company stock include Aladar Szalay, John Thomas, Sean Ryder, Caroline Jewett, Thomas Zindrick, Yong Yu, John W Smither, Joseph Cappello, Doug Samuelson and Qian Zhang. View institutional ownership trends. How do I buy shares of Genelux? Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GNLX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNLX Stock Alerts